- Qualitative analysis that evaluates eight markers: BAT25, BAT26, D2S123, D5S346, and D17S250, recommended by the National Cancer Institute (NCI) since 1997 and known as the Bethesda panel; and BAT40, NR21 and NR22, whose sensitivity and informativeness in different tissues has been demonstrated in numerous studies.
- The markers D2S123, D5S346 and D17S250, highly polymorphic in the population, when they do not suffer from instability, are sufficient to evaluate the coincidence of tumor and normal tissue, ensuring the traceability of the samples.
- Amplification range of 90-200 bp.
- Includes a genomic DNA control at the optimal amplification concentration, containing normal alleles for the markers amplified in the kit.
- For in vitro diagnostic use.
Are you a healthcare professional?
This content is intended exclusively for healthcare professionals.
The content is for informational purposes only and is not intended for the general public.